Satellos Bioscience with 55.3% Shareholder Turnout Elects All Directors, Reappoints PwC
MSLE•Shareholders representing 55.3% of Satellos Bioscience’s common shares elected all nine board nominees, with vote tallies ranging from 7.94 million (83.76%) to 9.48 million (99.99%). The meeting also approved PricewaterhouseCoopers LLP as auditors for the upcoming fiscal year.
1. Shareholder Meeting Participation and Director Elections
Satellos held its annual meeting on June 17, 2026, with shareholders present or represented by proxy accounting for 55.3% of issued and outstanding common shares. All nine nominees listed in the May 14, 2026 management information circular were elected to the board.
2. Vote Tally for Board Nominees
Vote counts ranged with Franklin M. Berger receiving 9,478,576 votes for (99.99%) and Iris Loew-Friedrich securing 7,939,800 votes for (83.76%), the lowest support level, while other directors saw approval rates above 92%. Detailed breakdowns showed against votes as low as 677 (0.01%) and as high as 1,539,453 (16.24%).
3. Auditor Reappointment
Shareholders also voted to reappoint PricewaterhouseCoopers LLP as the company’s auditors for the upcoming fiscal year, ensuring continuity in financial oversight and reporting.
4. Corporate Overview and Pipeline
Satellos is advancing SAT-3247, an oral small molecule targeting AAK1 to enhance muscle repair in degenerative diseases, currently in two Phase II trials for Duchenne muscular dystrophy. The company plans to explore additional indications based on its muscle regeneration platform.
